The 97-Year-Old Practice That Collapsed: What RAS Teaches Radiology About Scale Without Discipline

In July 2011 I walked into the headquarters of Radiological Associates of Sacramento to run a new teleradiology division. The CEO I was supposed to report to had been fired the Friday before. That was day one.

RAS was 94 years old at the time. By any reasonable measure of what makes a radiology group safe, they had it: 76 radiologists, 16 freestanding imaging centers, a service line that spanned interventional radiology, radiation oncology, vascular surgery, and urology, and an anchor relationship with Sutter Health that had been running continuously since 1923. Founded in 1917 when Dr. Harold Zimmerman brought Sacramento its first X-ray machine, RAS was the kind of practice you held up as an example. The kind that proved scale and longevity were a moat.

Two and a half years after that first day, on February 1, 2014, RAS ceased to exist.

I think about that timeline a lot, because it is the most important sentence in any conversation I have with a radiology group today. A 97-year-old institution can disappear in four years. Pedigree is not a moat. Scale is not a moat. The only thing that protects a practice is whether it has built the operational discipline to survive the decade it is currently in — not the one it grew up in.

How a 97-Year-Old Practice Actually Dies

The official story will tell you RAS was acquired by Sutter Health in a “new chapter” merger and that industry consolidation made it sensible. The press release version. Healthcare commentators noted at the time that 74% of physicians are now employed by hospitals or corporate entities, so what happened to RAS was simply the trend catching up.

Those of us who were inside the building in 2011, 2012, and 2013 know it was not a merger. It was a surrender. The WARN notices that went out after the acquisition told the truth more honestly than any press release — scores of positions eliminated as “duplicative.” Imaging centers absorbed. Radiation oncology absorbed. The independent practice that had carried Sacramento’s radiology for nearly a century became an org chart bullet inside a health system.

The mortal wound had been delivered before I arrived. In 2009, what should have been a routine renewal of the Sutter service agreement turned into a death sentence. According to the then-RAS CEO, the breaking point came when RAS announced it was bringing a struggling medical oncology group into the practice in October 2009. By March 2010, after nearly nine decades of continuous service to Sutter’s hospitals and the institutions that preceded them, the contract was over.

That is the entire story compressed into one paragraph. 87 years of business, dissolved in six months over a strategic move the anchor customer was never going to bless.

The Three Things That Actually Killed RAS

When I talk to radiology groups today, I get asked some version of this question on every call: “But what really happened?” People want a single villain — a bad contract, a bad partner, a bad CFO. The honest answer is that RAS died of three compounding mistakes, all of which look survivable in isolation and lethal in combination.

Concentration risk that nobody priced. When 87 years of your business runs through one anchor relationship, every other decision you make has to be filtered through whether it strengthens or threatens that relationship. RAS treated Sutter like a permanent fixture of the Sacramento landscape rather than a customer whose strategy could change. By 2009, hospital systems across the country were already reconsidering expensive outside contracts and pulling services in-house. The macro trend was visible. The internal posture — “they’ve been with us since 1923” — was not calibrated to it.

Diversifying in the wrong direction at the wrong moment. RAS’s response to a maturing market was to expand the practice into adjacent specialties — interventional, radiation oncology, vascular, urology, and finally a struggling medical oncology group in late 2009. On a whiteboard that looks like resilience: more service lines, more revenue surfaces, more value to the system. In practice, it pulled capital and management attention away from hardening the one relationship that mattered, and it added cost and complexity at the exact moment Sutter was telling the market it wanted cost control and integration. The medical oncology move was the trigger, but it was downstream of a years-long pattern of expanding the perimeter while neglecting the core.

Treating a new venture as a salvation strategy instead of a repositioning. This is where I came in. teleRAS launched in 2011 as the plan to replace the Sutter revenue. The pitch when I was recruited from Arizona was that we would win new contracts nationwide while the remaining radiologists kept reading locally. The math was supposed to balance. It never did. I spent that year hiring operations staff and signing teleradiology contracts with one hand while running layoff meetings with the other. Headcount went from 1,400 to 800 in the time I was there, and everyone in the building knew that number was not going to hold either.

teleRAS could have worked as a strategic repositioning — RAS becoming a different company than the one it had been since 1917. It could not work as a parallel revenue venture bolted onto a 94-year-old cost structure that was already too heavy for the business it had left. By the time the division existed, the lifeboats were already gone.

What Modern Radiology Groups Should Be Auditing Right Now

I tell every radiology group I work with that the lesson of RAS is not “diversify your contracts.” That is a slogan and it is mostly wrong. The actual lessons are uncomfortable.

The first is to look honestly at customer concentration and price the risk. If one health system relationship represents more than a third of your revenue, the question is not whether to diversify but whether your governance, your service-level discipline, and your willingness to invest in integration with that customer match the importance of the relationship. Most groups underinvest in their anchor customer because the relationship feels permanent. None of them are.

The second is to interrogate every expansion decision against the anchor relationship rather than against the org chart. New service lines, acquisitions, and joint ventures all look like growth. They are growth only if they make the anchor relationship more valuable to the anchor. RAS spent the decade before 2009 expanding into specialties Sutter did not need to buy from RAS. That was the long error. The medical oncology decision in 2009 was just where the bill came due.

The third is to be honest about what a new venture can and cannot do. A new division can reposition a practice. It cannot rescue one. The difference is whether the legacy cost structure is being restructured underneath the new venture, or whether the new venture is being asked to outrun decline. If you find yourself in the second posture, you are not in a growth conversation. You are in a wind-down conversation that has not been named yet.

Why This Matters in 2026

We are in a different decade than RAS was in 2009, but the structural pressure is the same and arguably worse. Hospital consolidation has accelerated. Big retail health entrants are pushing into 50-state telehealth footprints. Private equity is rolling up radiology groups at a rate that did not exist when RAS was negotiating its last renewal. The radiology groups that survive the next four years are not going to survive on pedigree. They are going to survive on operational discipline that the average 50-year-old practice has not yet built.

If “we’ve been here forever” is in your pitch deck, take it out. It is the most expensive sentence in the room.

By the time you realize you are on the Titanic, the lifeboats are already gone. RAS taught me that in a single year. I have spent every year since trying to make sure another group does not have to learn it the same way.

Talking to Yellowcross

Yellowcross was built by people who have run radiology operations through exactly the kinds of decisions RAS did not survive — concentration risk, expansion in the wrong direction, and the temptation to treat a new venture as a rescue plan. If you are leading an independent group right now and any of this sounds familiar, the conversation worth having is not about a new contract. It is about whether your operating model is calibrated to the decade you are actually in. We are happy to have that conversation. Start at yellowcross.com or read more on practice strategy in Building A Radiology Practice: Overcoming The Business Development Challenge.